Abstract:
:Activation of a patient's immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/tumor antigens. We recently found that epitope-optimized α-fetoprotein effectively activated CD8 T cells and generated potent antitumor effects in the carcinogen-induced autochthonous HCC mouse model. We predict that the same antigen engineering approach of epitope-optimization will enable us to develop effective human vaccines to prevent HCC recurrence after liver resection. The engineered human HCC vaccines may also allow us to identify high-affinity T-cell receptors and antibodies that can be used to reprogram T cells to treat HCC tumors via adoptive transfer.
journal_name
Immunotherapyjournal_title
Immunotherapyauthors
He Y,Hong Y,Mizejewski GJdoi
10.2217/imt.14.46subject
Has Abstractpub_date
2014-01-01 00:00:00pages
725-36issue
6eissn
1750-743Xissn
1750-7448journal_volume
6pub_type
杂志文章,评审相关文献
Immunotherapy文献大全abstract::Tumor immune evasion is one of the hallmarks of cancer, and expression of the B7 family of immune checkpoints (PD-L1, PD-L2, B7-H3, B7x and HHLA2) is one mechanism of immune evasion by tumors to suppress T-cell function. Antibodies blocking these interactions of B7-1/B7-2/CTLA-4 and PD-L1/PD-L2/PD-1 have had remarkabl...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2016-0001
更新日期:2016-06-01 00:00:00
abstract::Evaluation of: Bostrom J, Shang-Fan Y, Kan D et al.: Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009). The longstanding held notion that one antibody equals one antigen and, hence, one function has been challenged in recent years. Improved t...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.09.39
更新日期:2009-09-01 00:00:00
abstract::Background: Progress in immunotherapy (IT) has shifted treatment paradigms for multiple malignancies. In March 2019, the combination of nab-paclitaxel and atezolizumab was approved by the US FDA for patients with PD-L1 positive metastatic triple-negative breast cancer based on positive results of the Impassion130 tria...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0202
更新日期:2020-12-01 00:00:00
abstract::Histone deacetylase inhibitors possess a broad array of antitumor activities; however, their net impact on the evolving antitumor immune response is highly dependent on the inhibitors used and the histone deacetylases they target. Herein, we sequentially focus on each stage of the antitumor immune response - from dend...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2017-0134
更新日期:2017-12-01 00:00:00
abstract::The poor prognosis of pancreatic cancer patients signifies a need for radically new therapeutic strategies. Tumor-targeted oncolytic viruses have emerged as attractive therapeutic candidates for cancer treatment due to their inherent ability to specifically target and lyse tumor cells as well as induce antitumor effec...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.90
更新日期:2015-01-01 00:00:00
abstract:AIM:Previous studies showed that some patients after the treatment of anti-programmed cell death protein-1 (anti-PD-1) antibodies experienced immune-related diarrhea. In this study, we aim to explore the association between intestinal microbiota and immune-related diarrhea. METHODS:We obtained the fecal samples of 26 ...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2018-0144
更新日期:2019-04-01 00:00:00
abstract::Antibodies and antibody-based therapeutics have become big business, with annual sales over US$50 billion, accounting for >6% of worldwide pharmaceutical revenues. Ten molecules have blockbuster status (>US$1 billion), with six generating more than US$6 billion in sales. In excess of 300 products based on this rapidly...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt.12.5
更新日期:2012-03-01 00:00:00
abstract:AIM:This multicenter randomized placebo-controlled double-blind clinical trial investigated which maintenance dose shows the optimal benefit-risk ratio for subcutaneous immunotherapy with a Dermatophagoides pteronyssinus allergoid preparation. OBJECTIVE:To evaluate four maintenance doses of the allergoid preparation v...
journal_title:Immunotherapy
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.2217/imt-2018-0087
更新日期:2018-09-01 00:00:00
abstract::Chronic rhinosinusitis with nasal polyposis (CRSwNP) imparts a significant healthcare challenge, resulting in diminished quality of life for patients and high costs with resource utilization for disease management. Understanding of CRSwNP pathophysiology has progressively evolved and the identification of various infl...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2019-0191
更新日期:2020-02-01 00:00:00
abstract::While the etiology of multiple sclerosis (MS) remains unclear, research from the clinic and preclinical models identified the essential role of inflammation and demyelination in the pathogenesis of MS. Current treatments focused on anti-inflammatory processes are effective against acute episodes and relapsing-remittin...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2018-0153
更新日期:2019-02-01 00:00:00
abstract::HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20-30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This anti-HER2Th1 respo...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2016-0052
更新日期:2016-10-01 00:00:00
abstract::Rheumatoid arthritis (RA) is a chronic inflammatory disease in which persistent inflammation of synovial tissue results in a progressive functional decline of the joint and premature mortality. TNF inhibitors were the first biological disease-modifying antirheumatic drugs (DMARDs) used to treat RA. Since then, new bio...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.14.26
更新日期:2014-01-01 00:00:00
abstract::Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy hav...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0188
更新日期:2021-01-01 00:00:00
abstract:AIM:Placenta specific 1 (PLAC1) is a protein rarely expressed in normal cells, except it is important for placental development, with a possible role in the establishment of the mother-fetus interface. The gene is also highly active in a wide variety of cancers and therefore, immunization with PLAC1 peptides could poss...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0019
更新日期:2017-05-01 00:00:00
abstract::Hematopoietic stem cell transplantation is the treatment of choice for many hematologic malignancies and genetic diseases. However, viral infections continue to account for substantial post-transplant morbidity and mortality. While antiviral drugs are available against some viruses, they are associated with significan...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.43
更新日期:2015-01-01 00:00:00
abstract::Evaluation of: Boudousq V, Ricaud S, Garambois V et al.: Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing (125)I-labeled monoclonal antibodies. J. Nucl. Med. 51, 1748-1755 (2010). Mesothelioma, pseudomyxoma peritonei, ovarian and colon cancers, and s...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.11.11
更新日期:2011-04-01 00:00:00
abstract::Evaluation of: Fotin-Mleczek M, Duchardt KM, Lorenz C et al.: Messenger RNA-based vaccines with dual activity induce balanced TLR7-dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34(1), 1-15 (2011). Two decades ago, mRNA was proposed as an active pharmaceutical ingredient for the the...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.11.28
更新日期:2011-05-01 00:00:00
abstract::Injection of autologous tolerogenic dendritic cells is a promising strategy to diminish the burden of harmful immunosuppression in clinical transplantation. We discuss the immunoregulatory mechanisms triggered by this approach. Tolerogenic dendritic cells have long been associated with decreased antigen-processing cap...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.11.40
更新日期:2011-04-01 00:00:00
abstract::In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis. Its effect is asso...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0235
更新日期:2021-03-01 00:00:00
abstract::Although vaccination significantly reduces influenza severity, seasonal human influenza epidemics still cause more than 250,000 deaths annually. Vaccine efficacy is limited in high-risk populations such as infants, the elderly and immunosuppressed individuals. In the event of an influenza pandemic (such as the 2009 H1...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.11.167
更新日期:2012-02-01 00:00:00
abstract::In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, i...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.11.5
更新日期:2011-03-01 00:00:00
abstract::John L Stanford speaks to Hannah Wilson, Assistant Commissioning Editor John L Stanford is Chief Scientific Officer at BioEos Ltd (Kent, UK). Dr Stanford began his career as a senior lecturer and then reader in microbiology at Middlesex Hospital Medical School (London, UK), then University College London Medical Schoo...
journal_title:Immunotherapy
pub_type: 面试,新闻
doi:10.2217/imt.13.27
更新日期:2013-05-01 00:00:00
abstract:AIM:A 1-year follow-up study comparing the safety and tolerability of the dosing schedules, satisfaction and effectiveness of a novel microcrystalline tyrosine-adsorbed mite (Dermatophagoides pteronyssinus)-allergoid subcutaneous immunotherapy (Acarovac Plus™) in 30 adult patients (18-65 years) with allergic rhinitis a...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2016-0068
更新日期:2016-10-01 00:00:00
abstract::FOCIS goes South: Advances in Translational and Clinical Immunology was the first Federation of Clinical Immunology Societies (FOCIS) ( www.focisnet.org ) meeting held in Latin America (May 15-17, 2017, Santiago de Chile, Chile). The meeting was organized as a 3-day workshop and was fostered by the Millennium Institut...
journal_title:Immunotherapy
pub_type:
doi:10.2217/imt-2017-0079
更新日期:2017-09-01 00:00:00
abstract::Viral hemorrhagic fevers (VHFs) often cause high mortality with high infectivity, multiorgan failure, shock and hemorrhagic diathesis. Fibroblastic reticular cells (FRCs) within secondary lymphoid organs provide a supporting scaffold to T-lymphocyte areas. These cells regulate the movement of various immune cells and ...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/1750743X.1.2.187
更新日期:2009-03-01 00:00:00
abstract::Over the last two decades, anti-CD20 monoclonal antibody (mAb) therapy has improved patient outcome in B-cell malignancies, and confirmed CD20 as an important target in chronic lymphocytic leukemia (CLL). Until recently, the gold standard was based on the utilization of rituximab combined with chemotherapy (fludarabin...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2015-0015
更新日期:2016-05-01 00:00:00
abstract::Currently, limited data exist on the safety of pembrolizumab in patients with metastatic melanoma who have developed severe immune-related adverse events following treatment with ipilimumab. We report a 45-year-old male patient with BRAF-mutant metastatic melanoma who discontinued treatment with ipilimumab due to trea...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2015-0025
更新日期:2016-06-01 00:00:00
abstract::Waldenström macroglobulinemia (WM) is a lymphoproliferative lymphoma that is characterized by monoclonal immunoglobulin M (IgM) protein and bone marrow infiltration. Its incidence is rare and rarer still is its ability to transform to a B-cell lymphoma, particularly the aggressive diffuse large B-cell lymphoma, which ...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0027
更新日期:2017-08-01 00:00:00
abstract::Heat-shock proteins (HSPs) have been involved in different functions including chaperone activity, protein folding, apoptosis, autophagy and immunity. The HSP families have powerful effects on the stimulation of innate immune responses through Toll-like receptors and scavenger receptors. Moreover, HSP-mediated phagocy...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2018-0105
更新日期:2019-02-01 00:00:00
abstract::Immunotherapy of cancer is a rapidly developing field; one such development is the manipulation and use of natural killer (NK) cells. These cells with 'killer instincts' are an attractive cell to utilize, as they are directly reactive toward tumor and could potentially activate the endogenous adaptive immune system. T...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.09.36
更新日期:2009-07-01 00:00:00